What is dorsal root ganglion stimulation for CRPS?

Dorsal root ganglion stimulation uses an implanted device to send electrical pulses to the dorsal root ganglion, where sensory nerves leave the spine. FDA approved it in February 2016 for lower limb pain in adults with complex regional pain syndrome. In the ACCURATE trial, 81.2 percent met the success measure at three months, against 55.7 percent with spinal cord stimulation.

A painted apothecary bottle and mortar with a poppy and lupine.

What is the dorsal root ganglion, and how does a DRG stimulator work?

The dorsal root ganglion is a nerve structure beside the spinal cord, at the point where sensory nerves exit the backbone. A dorsal root ganglion (DRG) stimulator delivers electrical pulses to that structure. The ACCURATE trial's registry record describes the device as two implanted parts: a pulse generator placed under the skin of the buttocks or abdomen, and up to four leads that run from the generator to the target area.

The 2022 practical guidelines in Pain Medicine describe the difference from a conventional spinal cord stimulator. Conventional stimulation acts on pain pathways in the dorsal column of the spinal cord, and DRG stimulation "modulates pain signal pathways at the level of the dorsal root."

What is DRG stimulation approved for in the United States?

FDA's 2016 approval of DRG stimulation covers lower limb pain from CRPS. FDA's premarket approval record P150004 shows that the agency approved the Axium Neurostimulator System on February 11, 2016. The approved indication is "the management of moderate to severe chronic intractable pain of the lower limbs in adult patients with Complex Regional Pain Syndrome (CRPS) types I and II."

The FDA record adds a note about who was studied. Subjects in the ACCURATE study "had failed to achieve adequate pain relief from at least 2 prior pharmacologic treatments from at least 2 different drug classes." The 2016 approval record does not list CRPS of the arm or hand.

Who took part in the ACCURATE trial?

The ACCURATE trial enrolled 152 adults with CRPS or causalgia in a lower limb at 22 sites in the United States. Deer and colleagues published the results in the journal Pain in 2017, and the trial is registered as NCT01923285. The registry record lists the entry rules. Participants were aged 22 to 75 and had lower limb pain for at least six months, with a pain score of at least 60 on a 100 mm scale. Each had tried at least two drugs from two classes without adequate relief.

The trial excluded several groups. The registry record excludes people whose pain was mainly in the back, people who had previously failed spinal cord stimulation, and people "currently involved in medically related litigation, including workers compensation." Participants were assigned at random, 76 to DRG stimulation and 76 to a commercially available spinal cord stimulator.

What did the ACCURATE trial find at 3 and 12 months?

The ACCURATE trial found a higher rate of treatment success with DRG stimulation than with spinal cord stimulation at both time points. Success meant at least 50 percent pain relief during the temporary trial phase and at follow-up, with no stimulation-related neurological deficit. At 3 months, 81.2 percent of the DRG group and 55.7 percent of the spinal cord stimulation group met that measure. At 12 months the figures were 74.2 percent (49 of 66) and 53.0 percent (35 of 66).

No participant reported a stimulation-related neurological deficit. People using DRG stimulation also reported less change in the tingling sensation when they moved between lying down and standing.

How did the two devices compare in the ACCURATE trial?

The published ACCURATE paper reports the following figures for the two groups, with success rates favoring dorsal root ganglion stimulation and procedure-related events favoring spinal cord stimulation.

ACCURATE trial results: dorsal root ganglion stimulation compared with spinal cord stimulation (Deer et al., Pain, 2017)
MeasureDorsal root ganglion stimulationSpinal cord stimulation
Participants randomized in ACCURATE7676
Treatment success at 3 months in ACCURATE81.2 percent55.7 percent (39 of 70)
Treatment success at 12 months in ACCURATE74.2 percent (49 of 66)53.0 percent (35 of 66)
Serious adverse events in ACCURATE10.5 percent (8 of 76)14.5 percent (11 of 76)
Procedure-related adverse events in ACCURATE46.1 percent (35 of 76)26.3 percent (20 of 76)
Mean implant procedure time in ACCURATE107.2 minutes75.7 minutes

What are the limits of the ACCURATE trial?

The ACCURATE trial has four limits that affect how far its results reach. First, it compared two implanted devices. It had no sham device and no group receiving usual medical care, so it does not show how DRG stimulation compares with no implant. Second, the published paper states that subjects, investigators and site staff "were not blinded."

Third, the paper states that the study "was sponsored by Spinal Modulation, LLC, a wholly owned company of St. Jude Medical," the maker of the device, and several authors were company employees. Fourth, the trial covered lower limb pain only. The authors also note that participants who dropped out were counted as failures, so differences in who stayed in each group could have influenced the success rates.

Did DRG stimulation cause more procedure problems than spinal cord stimulation?

Yes, for non-serious problems tied to the implant procedure. In the ACCURATE trial, 35 patients (46.1 percent) in the DRG group reported a procedure-related adverse event, compared with 20 patients (26.3 percent) in the spinal cord stimulation group, a statistically significant difference. Pain at the incision site was the most frequent event in both groups.

Serious adverse events did not differ significantly: 10.5 percent in the DRG group and 14.5 percent in the spinal cord stimulation group. The authors linked the higher rate of procedure-related events to longer DRG procedures, which averaged 107.2 minutes against 75.7 minutes, and to the larger number of leads placed in some DRG patients.

What did the post-approval study of DRG stimulation report?

The post-approval study reported a serious adverse event rate of 8.7 percent at 12 months among people who received a permanent DRG implant. FDA's approval record shows a post-approval study protocol approved in May 2016. The post-approval study, called TARGET, is registered as NCT02800863. The registry results show that 426 people with lower limb CRPS enrolled and 296 received a permanent implant.

For 213 implanted participants measured at 12 months, the registry reports a mean change in pain score of 44.48 percent from baseline, with a standard deviation of 34.15. TARGET had a single group and no comparison treatment, and 198 of the 426 enrolled participants completed it. Like ACCURATE, TARGET excluded people involved in medically related litigation, including workers' compensation.

What do the guidelines say about DRG stimulation for CRPS?

The guidelines describe DRG stimulation as a later-stage option with evidence that still needs confirmation. The 2022 practical guidelines grade the ACCURATE trial as level 2 evidence. They also cite a 2020 pooled analysis by Huygen and colleagues of 217 patients with a permanent DRG implant at 12 months, in which 63 percent had at least 50 percent pain relief. The guidelines conclude that "there is evidence supporting SCS and DRG for the treatment of CRPS, but high-quality and corroboratory evidence is needed."

The Royal College of Physicians' 2018 guideline groups DRG stimulation with spinal cord stimulation under neuromodulation and adds a caution: "The long-term evidence for the latter, newer technology has not yet been established."

Has DRG stimulation been tested against a sham device?

A sham-controlled study has been registered, and its results were not posted when this page was checked. Umea University in Sweden registered a randomized, double-blind crossover trial, NCT07170722, comparing active DRG stimulation below the level a person can feel with the device switched off. The registry lists 20 participants who already had a DRG stimulator for chronic neuropathic pain, and a completion date of November 2025.

Rush University Medical Center in Chicago registered a second study, NCT04909138, which compares two intermittent stimulation settings in people who have had a DRG stimulator for at least a year. The Swedish study enrolls people with chronic neuropathic pain of any cause, and neither study has a California site.

What has been reported to FDA about DRG stimulators?

FDA files adverse event reports for DRG stimulators under device product code PMP, and the counts are published through its openFDA service. The reports are unverified, can duplicate one another, and do not establish that the device caused the event. FDA does not publish how many DRG stimulators have been implanted, so the counts are not rates. The page on spinal cord stimulation shows the report counts and recent recalls for spinal cord and DRG stimulators together.

Common questions

One randomized trial favored DRG stimulation for CRPS of the lower limb. In the ACCURATE trial, 81.2 percent of the DRG group and 55.7 percent of the spinal cord stimulation group met the success measure at 3 months. The trial was unblinded, was sponsored by the device maker, and had no sham or usual-care group. The 2022 practical guidelines state that "high-quality and corroboratory evidence is needed."

The 2016 FDA approval record does not list it. FDA's approval record for the Axium system limits the indication to chronic intractable pain "of the lower limbs" in adults with CRPS types I and II, and the ACCURATE trial enrolled only people with lower limb pain. The trial's registry record excluded people whose pain was only in a cervical distribution. Published randomized evidence for the arm or hand was not found for this page.

FDA approved the Axium Neurostimulator System, a dorsal root ganglion stimulator, on February 11, 2016, under premarket approval number P150004. The record lists Abbott Medical as the applicant. The 2022 practical guidelines likewise state that DRG therapy "was brought to market in the United States in 2016." The record shows a post-approval study protocol approved in May 2016.

In the ACCURATE study it did. Participants had a temporary trial phase that averaged 5.8 days in both groups. A participant moved on to a permanent implant only after reporting at least 50 percent relief of lower limb pain during the trial and wanting to continue. Of the 76 people assigned to DRG stimulation, 61 received a permanent implant. People who failed the trial phase were counted as treatment failures in the results.

Randomized data end at 12 months. The ACCURATE trial reported treatment success in 74.2 percent of the DRG group at 12 months, down from 81.2 percent at 3 months. The paper notes that participants had to keep pain medication stable only through 3 months, so later results may reflect medication changes. The Royal College of Physicians' 2018 guideline states that long-term evidence for the technology "has not yet been established."

The registry records do not give a reason. Both the ACCURATE trial and the TARGET post-approval study list current involvement "in medically related litigation, including workers compensation" as an exclusion. One result is that the published figures describe people who had no pending injury lawsuit or workers' compensation claim over their medical condition.

Sources

Every source below was opened and read for this page. The date is when it was last checked.

  1. Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months: a randomized comparative trialStudy · Pain (Deer et al.), 2017 · checked
  2. ACCURATE trial of the AXIUM Neurostimulator System in the treatment of chronic pain (NCT01923285), with posted resultsStudy · ClinicalTrials.gov (Abbott Medical Devices) · checked
  3. Premarket Approval P150004: Axium Neurostimulator SystemGovernment agency · U.S. Food and Drug Administration, 2016 · checked
  4. TARGET Post-Approval Study of dorsal root ganglion stimulation (NCT02800863), with posted resultsStudy · ClinicalTrials.gov (Abbott Medical Devices) · checked
  5. Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 5th EditionClinical guideline · Pain Medicine (Harden et al.), 2022 · checked
  6. Complex regional pain syndrome in adults: UK guidelines for diagnosis, referral and management in primary and secondary care, 2nd editionClinical guideline · Royal College of Physicians, 2018 · checked
  7. openFDA device adverse event and recall dataDataset · U.S. Food and Drug Administration · checked
  8. Sub-threshold DRG Stimulation vs Sham in Established Responders (NCT07170722)Study · ClinicalTrials.gov (Umea University) · checked
  9. Intermittent Dosing of Dorsal Root Ganglion Stimulation as an Alternate Paradigm to Continuous Low-Frequency Therapy (NCT04909138)Study · ClinicalTrials.gov (Rush University Medical Center) · checked

Ask a lawyer about your CRPS case

Free case review. No fee unless we recover. A person from Wise Law reads every message.

What happened before the CRPS started? (optional)
Has a doctor diagnosed CRPS? (optional)
Or call (424) 235-7879

Submitting this form does not create an attorney-client relationship. An attorney-client relationship is formed only by a signed written fee agreement.

Text usCall